News

Under the terms of the agreement, LakePharma will have the ability to offer Twist’s proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as

The approval was based on data from Archer 1050 randomized, multicenter, multinational and open-label phase 3 study conducted in patients with unresectable, metastatic or recurrent NSCLC harboring EGFR

Pegfilgrastim is a long-acting version of filgrastim and may be prescribed to appropriate cancer patients undergoing chemotherapy to enhance the production of infection-fighting white blood cells2. Studies have

These results were presented at the 25th Annual Conference of the British HIV Association (BHIVA) taking place from 2-5 April in Bournemouth, UK. Professor Chloe Orkin, Consultant Physician

As part of a research and license agreement, Astellas Pharma will be able to use Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. The

QUE Oncology is developing drugs for large unmet medical needs and has already advanced clinical development of its lead drug program Q-122, through four Phase 1 trials. QUE

Data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts. Eight patients total were dosed. Based

In this connection, the regulator approved the company’s Investigational New Drug (IND) application to begin the early stage trial for UCARTCS1. The allogeneic CAR-T therapy is based on

IFM Tre, which was launched in July 2018, is currently developing a suite of NLRP3 antagonists for the treatment of inflammatory diseases. NLRP3, which expands to NOD-, LRR-